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Abstract 
A catalytic protocol for the base-mediated amidation of unactivated esters with amino alcohol 
derivatives is reported. Investigations into mechanistic aspects of the process indicate the reaction 
involves an initial transesterification, followed by an intramolecular rearrangement. The reaction is 
highly general in nature, and can be extended to include the synthesis of oxazolidinone systems 
through use of dimethyl carbonate.  
 
Introduction 
The amide bond is a pivotal functional group from consideration of both chemistry and 
biology.1,2 In an industrial context, formation of the amide bond represents the single largest subset of 
all reactions conducted in medicinal chemistry laboratories,3,4 which further underlines the importance 
of this ubiquitous functionality. Accordingly, considerable investment has been made in the 
development of synthetic methodology which enables this transformation in a mild and efficient 
manner, and a broad palette of reagents has now emerged from these efforts.5 Having stated this, the 
majority of reagents currently available to facilitate amide bond formation are stoichiometric in 
nature, and the poor atom economy associated with their use has prompted calls for their replacement 
by more efficient and sustainable alternatives.6 Given the urgent requirement to address this important 
issue, a number of catalytic approaches to amide bond formation have emerged in recent years.7 For 
example, these methods include the use of transition metal catalysts,8,9,10 boron-derived species,11,12,13 
or enzymes.14 Although many of these catalytic processes have wide utility, they are often associated 
with some limitations, including use of high temperatures, unsustainable rare earth metals, or 
extended reaction times. 
 We recently reported a base-mediated process for the catalytic preparation of amides from 
esters and amino alcohol derivatives.15 Through a combination of reaction screening where we 
explored a range of organic and inorganic bases and application of Design of Experiments 
optimization methods,16 it was possible to develop a mild, efficient, and unprotracted procedure for 
the synthesis of amides from unactivated ester derivatives and amino alcohols using a catalytic (10 
mol%) quantity of tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine 
(BEMP, 2)17 as a base (Scheme 1). The reaction was posited to proceed through an initial 
transesterification event mediated by BEMP which liberates an equivalent of alcoxide base capable of 
catalyzing a further reaction cycle. Rearrangement of the intermediate ester is then thought to lead to 
the thermodynamically more stable amide product (1). In this study, we present our work in relation 
to the mechanistic aspects of this base-catalyzed process, as well as a complete report on the scope 
and limitations of the reaction. Additionally, we demonstrate the applicability of the process to a new 
reaction manifold enabling the synthesis of oxazolidinone derivatives. 
  
Scheme 1. Organobase-mediated amidation of esters with amino alcohols. 
 
Results and Discussion 
Investigation into reaction mechanism. As intimated in Scheme 1, we reasoned that the 
reaction proceeds via an initial transesterification process, to yield an intermediate ester represented 
by 4. Based on this, we aimed to independently prepare a compound of this type and determine if it 
was capable of undergoing the requisite rearrangement to the observed amide product. Scheme 2 
depicts the preparation of an appropriate test substrate, using D ¶-carbonyldiimidazole (CDI) 
mediated esterification,18 followed by acidolysis of the Boc protecting group to yield the salt 6. We 
initially attempted to isolate intermediate ester 6 using the conditions established in Scheme 1 (10 
mol% BEMP in MeCN), however, this was not successful as presumably the esterification is 
reversible if rearrangement to the amide cannot take place. Treatment of 6 with an organic base then 
enabled smooth conversion to the desired amide product 7 in high yield (95%). This result indicated 
that the intermediate esters represented by 4 (Scheme 1) were competent in rearranging to the amide 
product.  
 
 Scheme 2. Preparation of an ester intermediate to probe mechanism. 
 
Previously, we had considered this process to be intramolecular in nature. Accordingly, we 
designed a series of probe molecules to confirm this proposal, and exclude any potential 
intermolecular amidation pathways. In the first instance, we conducted a competition experiment, 
condensing ethanolamine and propylamine with methyl phenylacetate (Scheme 3). In this case, the 
exclusive product obtained was ethanolamine-derived amide 8 in high yield, supporting the view that 
a more favourable transesterification and subsequent intramolecular rearrangement was operative. 
 
 
Scheme 3. Competition experiment. 
  
With this information in hand, we then designed a series of probe molecules which could 
offer additional support to the notion of an intramolecular rearrangement. Accordingly, we examined 
the effect of homologation of the amino alcohol partner on reaction yield (Figure 1). Increasing the 
chain length would be anticipated to have a deleterious effect on conversion due to the increased 
flexibility of the system, which then disfavours the required rearrangement of the proposed 
intermediate ester to the target amide. Additionally, when increasing the chain length of the amino 
alcohols, the cyclic transition states arising from the proposed intramolecular rearrangement increase 
from a five membered ring with ethanolamine, through to an eight membered ring with 
pentanolamine. The strain associated with the differing cycle sizes are calculated as follows: five 
membered, 6 kcal/mol; six membered, 0.1 kcal/mol; seven membered, 6.2 kcal/mol; eight membered, 
9.7 kcal/mol.19 From consideration of this aspect of the reaction, it can again be reasoned that longer 
chain amino alcohols should be less competent substrates. If an intermolecular process leading to a 
direct amidation was applicable, then it could be anticipated that the reaction yield would not be 
significantly affected by homologation over the range examined in the current study. Consideration of 
a range of products with increasing chain length (8, 10a-c, Figure 1) under the standard conditions 
outlined in Scheme 1 confirms this to be the case; extending the chain length to the butanolamine 
analogue 10b results in a significant erosion in yield compared to 10a, with the pentanolamine system 
10c completely failing to form. The effect of the acidic pKa of the alcohol moiety is not believed to 
influence the observed yield; if an increase in acidic pKa was noted then it would disfavour initial 
deprotonation and retard the overall process. Consideration of the relevant pKa values for 
propanolamine, butanolamine and pentanolamine are all around 15,20 indicating the differences in 
reactivity observed in homologating the amino alcohol species are unlikely to be attributable to 
changes in pKa. These results lend further credence to the initial hypothesis of an intramolecular 
rearrangement following transesterification. 
 We next examined a further set of substrates (10d-f, Figure 1) which could provide additional 
evidence in support of our proposed mechanism. The 4-hydroxypiperidine amide 10d is a 
conformationally locked analogue of the propanolamine derivative 10a and was thus anticipated to be 
too constrained to undergo rearrangement to the amide following transesterification, which is 
consistent with the conversion observed in this case. Additionally, the benzylamine-derived product 
10e is not an effective substrate from both enthalpic and entropic considerations.  An analogous amide 
product 10f was successfully isolated, albeit in reduced yield in comparison to aliphatic-based 
progenitors, indicating the tolerance of phenols as substrates. By contrast, however, the isomeric 
amide system 10g did not form under the standard conditions developed, presumably due to the lower 
nucleophilicity of the aniline in the context of the ester rearrangement, which indicates a potential 
limitation of the current approach with this class of substrate.  
 Figure 1. Mechanistic probes evaluated. (a) RHDFWLRQSHUIRUPHGDWÛ& 
 
 In the last part of this aspect of the study, we sought to establish relative rates of conversion 
between a secondary amine in comparison with a primary amine, and upon comparing an amino diol 
with an amino alcohol. Compounds 11a and 11b (Figure 2) could be isolated in excellent yields (91 
and 88%, respectively) using the existing protocol and these were used together with compound 8 to 
assess conversion to each product as a function of time. The data which emerged from this experiment 
indicated rapid conversion to product in each case and in a relatively short timeframe (less than one 
hour). There was little difference between any of the substrates in terms of their rates of conversion, 
with the amino diol 11b exhibiting a marginally faster temporal profile. No evidence for the 
corresponding ester intermediates could be detected in the HPLC assay, suggesting this is potentially 
the rate determining step and rearrangement to amide product is extremely rapid in each case.   
 
 
 Figure 2.  Assessment of conversion as a function of time. (a) Determined by HPLC using an internal 
standard. 
Scope of the amidation process. In the second part of this study, we aimed to more fully 
delineate the scope of the reaction. In order to evaluate this, a broad range of ester derivatives and 
amino alcohols were examined using the established reaction conditions (10 mol% BEMP, MeCN, 
URRP WHPSHUDWXUHRUÛ&, 15 h), and the results of this survey are presented in Figure 3. Various 
substituted benzamide systems (12a-e) can be readily accessed and in good to excellent yield. Again, 
where yields are lower at room temperature, application of modest heating (12b) is effective in 
furnishing high yields. Aliphatic ester derivatives (12f-h) also perform well in the reaction which is 
useful for the synthesis of lead-like compounds21 in a discovery chemistry setting exemplified by 12g 
and 12h. In relation to this, the synthesis of heterocyclic amide derivatives is an important objective in 
a medicinal chemistry effort,22 therefore evaluation of the current methodology using such substrates 
is warranted. Accordingly, a raft of different heterocyclic motifs exemplified by compounds 12i-t 
were examined. Pyridine (12i, 12l), pyrimidine (12k, 12p), pyrazine (12j), pyrrole (12o), thiophene 
(12q)  and furan (12r) all perform well along with saturated heterocyclic motifs such as 12s and lead-
like architectures such as 12t.  Focusing on the triazole-derived motifs, compound 12m was isolated 
in a low yield of 28%. However, we attribute this to the poor solubility of both the ester starting 
material and product itself in the reaction solvent. By contrast, the corresponding methylated analogue 
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12n is completely soluble in the reaction milieu, which is reflected in the excellent yield (94%) 
obtained with this compound. 
 
Figure 3. Scope of amide synthesis with straight chain amino alcohols. 
Additionally, to enable a direct comparison between the current catalytic approach and 
existing stoichiometric methods, we independently prepared the pyrimidine derivative 12p using 
N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uroniumhexafluorophosphate (HATU)23 as a coupling 
agent with the corresponding  carboxylic acid (Scheme 4). Pleasingly, the catalytic approach 
described here performs well in comparison to a standard coupling reagent, furnishing 12p in a 
slightly improved yield over the existing method, with the clear advantage of obviating the need for 
stoichiometric reagents and generation of associated by-products 
.  
 
Scheme 4. Comparative synthesis of 12b with stoichiometric reagents. 
 
 In addition to the straight-chain amino alcohol systems discussed above, we also examined 
further range of substrates as outlined in Figure 4. (S)-Prolinol proved to be an effective nucleophile 
with benzoate esters (13a), cinnamate derivatives (13b), heterocyclic systems (13c, 13d) as well as 
alkyl esters (13e). Amide 13a was also prepared from methyl 4-bromo-2-chlorobenzoate and (S)-
prolinol on a 2.5 g scale in excellent yield, which serves to demonstrate the utility of the method for 
larger scale synthesis. Other amino alcohols derived from proteinogenic amino acids such as 
phenylalaninol were also competent substrates in the reaction (13f) allowing access to peptidic 
structures. Further evaluation of secondary amine derivatives as nucleophiles showed that these to be 
robust substrates as exemplified by compounds 13g and 13h. As discussed above, amino diols 
performed well in the reaction and amide 13i is a further example of this substrate class. Secondary 
and tertiary alcohols represent a more significant challenge which can be ascribed to a more 
demanding initial transesterification reaction. Having stated this, application of modest heating 
enabled the isolation of 13j in good yield using our catalytic process. In the case of tertiary alcohols, 
we could not prepare amides from electron-neutral substrates such as methyl phenylacetate (leading to 
13k), suggesting a possible limitation of the methodology. However, when more electron withdrawing 
esters are employed, the corresponding products such as 13l can be isolated in preparatively useful 
yield. It was not possible to identify any ester intermediate in the reaction to form 13l indicating rapid 
rearrangement to the thermodynamically favourable amide, as noted previously.  
 
 Figure 4. Scope of amino alcohol component. DJVFDOHLQSXWESHUIRUPHGDWÛ& 
  
In the concluding part of our study, we turned our attention to application of the methodology to the 
synthesis of oxazolidinone derivatives. These important heterocyclic motifs are used widely in both 
asymmetric synthesis24 and medicinal chemistry,25 therefore a mild and efficient approach to their 
synthesis would be attractive. Typically, oxazolidinones are synthesized by the reaction of a suitable 
amino alcohol and diethyl carbonate in the presence of excess base (e.g. K2CO3, NaOMe) whilst 
heating, usually to temperatures in excess of 100 °C.26 Given that we had established that formation of 
an intermediate ester followed by cyclisation to an amide was taking place in the amidation reaction, 
it was reasoned that this could be exploited in the synthesis of oxazolidinones. Adapting the reaction 
conditions outlined above could potentially offer a favourable alternative to the typical synthesis of 
such compounds, having the advantage of being performed at significantly lower temperatures and 
through the use of catalytic amounts of base. A brief survey of stoichiometry of the dimethylcarbonate 
(DMC) starting material was carried out in a model reaction with phenylalaninol (Table 1). Given the 
low cost and abundance of DMC in relation to the amino alcohol precursors, we elected to use an 
excess of this reagent. To afford the highest probability of success, we also examined the use of 
slightly elevated temperatures from the outset. 
 Entry 
Dimethyl carbonate 
(equiv.) 
Conversion (%)
a
 
1 1 68 
2 3 72 
3 5 69 
4 6 (neat) 61 
 
Table 1. Survey of conditions for oxazolidinone synthesis. (a) Determined by HPLC using an internal 
standard. 
Pleasingly, we observed good levels of conversion to the desired product in each of the reactions 
attempted. From this short screening exercise, we confirmed that 3 equivalents of the carbonate 
component was optimal, which provided encouragement to explore the synthesis of a small range of 
oxazolidinone derivatives using this approach (Figure 5). 
 
 
Figure 5. Application to the synthesis of oxazolidinone systems. 
 Considering the focused sub-set outlined in Figure 5, a range of oxazolidinone derivatives 
could be prepared using an appropriate amino alcohol and dimethyl carbonate under relatively mild 
conditions using catalytic BEMP, and in generally good yield. Amino alcohols derived from 
proteinogenic amino acids were very effective in the reaction (14a-c, 14e), while ethanolamine gave 
acceptable yields of oxazolidin-2-one (14d). Aminodiols were also tolerated in this process, leading to 
products such as 14f in excellent isolated yield. 
 
Conclusion 
A mild and efficient synthesis of amide derivatives from esters and amino alcohols has been 
reported using an organic base as a catalyst. The full scope of the reaction has been evaluated 
including application towards amide products of potential pharmaceutical relevance and extension of 
the methodology towards the preparation of the versatile oxazolidinone motif. Additionally, through 
design and study of appropriate probe molecules, the mechanism of the reaction has been delineated, 
indicating an initial transesterification is taking place, followed by rapid and facile rearrangement to 
the corresponding amide products. 
 
Experimental Section 
General Methods. All reagents and solvents were used as obtained unless otherwise stated. 
Purification was carried out according to standard laboratory methods.27 BEMP was purified by 
vacuum distillation from CaH2 and stored in a septum-sealed oven-dried flask over previously 
activated 4 Å molecular sieves and purged with and stored under nitrogen. Reactions were carried out 
under Schlenk conditions using oven-dried glassware, which was evacuated and purged with N2 
before use. Thin layer chromatography was carried out using aluminium-backed silica plates which 
were analysed under 254 nm UV light or developed using potassium permanganate solution. Flash 
chromatography was carried out using prepacked silica cartridges. 1H NMR spectra were recorded at 
400 or 500 MHz and 13C NMR spectra were recorded at 101 or 126 MHz. Chemical shifts are 
reported in ppm and coupling constants are reported in Hz with CDCl3 referenced at 7.27 (
1H) and 
77.23 ppm (13C), and DMSO referenced at 2.50 (1H) and 39.51 ppm (13C). Mass spectrometry data 
was generated using a TOF analyser. Optical rotations were measured at 589 nm, with concentrations 
reported in g per 100 mL. Conversions were determined by HPLC using iodobenzene as an internal 
standard. The data for products 8, 12a, 12b, 12c, 12f, 12i, 12q, 12r, 13c, 13e, 13f and 13j were 
reported in our earlier communication.15 
  
2-((tert-Butoxycarbonyl)amino)ethyl benzoate (5).
28 To a solution of benzoic acid (341 mg, 
2.8 mmol) in CH2Cl2 (2 mL) was added CDI (456 mg, 3 mmol) and Et31ȝ/PPRO7KH
reaction mixture was stirred at room temperature for 16 h, then washed with water, dried (MgSO4), 
filtered, and concentrated to a residue that was purified by flash column chromatography (25% ethyl 
acetate/petroleum ether) to afford the title compound as a white solid (653 mg, 88%): Xmax (neat) 
3375, 1701, 1530 cm-1; 1H NMR (500 MHz, CDCl3): GH 8.07 ± 8.04 (m, 2H), 7.58 (tt, J = 7.5, 1.5 Hz, 
1H), 7.47 ± 7.43 (m, 2H), 4.87 (br. s, 1H), 4.39 (t, J = 5.5 Hz, 2H); 3.54 (d, J = 4.5 Hz, 2H), 1.45 (s, 
9H); 13C NMR (126 MHz, CDCl3) GC 166.7, 156.0, 133.3, 130.1, 130.0, 128.6, 79.8, 64.5, 40.0, 28.6; 
HRMS (ESI) m/z: [M+Na]+ Calcd for C14H19NO4Na 288.1204, Found 288.1204. 
2-(Benzoyloxy)ethanaminium 2,2,2-trifluoroacetate (6) To a solution of 2-((tert-
butoxycarbonyl)amino)ethyl benzoate (5, 398 mg, 1.5 mmol) in CH2Cl2 (1 mL) was added 
trifluoroacetic acid (1 mL). The reaction mixture was stirred at room temperature for 16 h, heated at 
Û&for 24 h then concentrated under vacuum to afford the title compound as a white solid (381 mg, 
91%): Xmax (neat) 3330, 3107, 2967, 1725, 1544 cm-1; 1H NMR (500 MHz, DMSO) GH 8.09 (dd, J = 
8.2, 1.3 Hz, 2H), 8.03 (br. s, 2H), 7.69 (tt, J = 7.3, 1.3 Hz, 1H), 7.57 ± 7.54 (m, 2H), 4.44 (t, J = 5.8 
Hz, 2H), 3.25 (q, J = 4.7 Hz, 2H), 1H missing (exchangeable); 13C NMR (126 MHz, DMSO) GC 
165.6, 133.6, 129.6, 129.3, 128.6, 61.5, 38.0; HRMS (ESI) m/z: [M]+ Calcd for C9H12NO2 166.0863, 
Found 166.0858. 
N-(2-Hydroxyethyl)benzamide (7).
15 To a solution of 2-aminoethyl benzoate (6, 381 mg, 1.37 
mmol) in CH2Cl2 (3 mL) was added Et31ȝ/PPRO7KHUHDFWLRQPL[WXUHZDVVWLUUHGDW
room temperature for 16 hours then concentrated to a residue that was purified by flash column 
chromatography (5% methanol/CH2Cl2) to afford the title compound as a white solid (306 mg, 95%): 
Xmax (neat) 3296, 2937, 2876, 1634, 1537 cm-1; 1H NMR (500 MHz, CDCl3) GH 7.80 ± 7.78 (m, 2H), 
7.51 (tt, J = 7.3, 1.6 Hz, 1H), 7.45 ± 7.41 (m, 2H), 6.75 (br. s, 1H), 3.83 (t, J = 5.0 Hz, 2H), 3.63 (q, J 
= 5.2 Hz, 2H), 2.16 (br. s, 1H); 13C NMR (126 MHz, CDCl3) GC 168.9, 134.3, 131.9, 128.8, 127.2, 
62.6, 43.1; HRMS (ESI) m/z: [M+H]+ Calcd for C9H12NO2 166.0863, Found 166.0860. 
General Procedure for Base-Catalysed Amide Bond Formation To an oven-dried Schlenk 
WXEHFRQWDLQLQJ%(03ȝ/PPRODQGDFHWRQLWULOH ȝ/ZDVDGGHGHVWHU PPRO) 
and amino alcohol (1.42 mmol). The reaction mixture was stirred at room temperature or 40 °C for 15 
h then concentrated to a residue that was purified by flash column chromatography (methanol/ 
CH2Cl2). For oxazolidinone synthesis, the ester was replaced wLWKGLPHWK\OFDUERQDWHȝ/
mmol). 
N-(3-Hydroxypropyl)-2-phenylacetamide (10a).
29
 White solid (220 mg, 80%): Xmax (neat) 
3310, 3242, 3067, 2945, 2882, 1655, 1564 cm-1; 1H NMR (400 MHz, DMSO) GH 8.01 (t, J = 4.4 Hz, 
1H), 7.31 ± 7.19 (m, 5H), 4.42 (t, J = 4.8 Hz, 1H), 3.40 ± 3.38 (m, 4H), 3.09 (q, J = 6.5 Hz, 2H), 1.54 
(app. quin, J = 6.7 Hz, 2H); 13C NMR (101 MHz, DMSO) GC 170.0, 136.6, 128.9, 128.2, 126.3, 58.4, 
42.4, 35.8, 32.4; HRMS (ESI) m/z: [M+Na]+ Calcd for C11H15NO2Na 216.0995, Found 216.0991. 
N-(4-Hydroxybutyl)-2-phenylacetamide (10b).30 White solid (118 mg, 40%): Xmax (neat) 3358, 
3291, 2951, 1636, 1541 cm-1; 1H NMR (400 MHz, DMSO) GH 8.01 (t, J = 5.0 Hz 1H), 7.31 ± 7.18 (m, 
5H), 4.38 (t,  J = 5.2 Hz, 1H), 3.39 ± 3.35 (m, 4H), 3.05 ± 3.00 (m, 2H), 1.43 ± 1.37 (m, 4H); 13C 
NMR (101 MHz, DMSO) GC 169.8, 136.6, 128.9, 128.1, 126.2, 60.4, 42.4, 38.5, 29.8, 25.8; HRMS 
(ESI) m/z: [M+Na]+ Calcd for C12H17NO2Na 230.1152, Found 230.1146. 
N-(2-Hydroxybenzyl)-2-phenylacetamide (10f). White solid (161 mg, 47%): Xmax (neat) 3279, 
3102, 2569, 1626, 1568 cm-1; 1H NMR (400 MHz, CDCl3) GH 9.47 (br. s, 1H), 7.41 ± 7.35 (m, 3H), 
7.29 ± 7.25 (m, 3H), 7.10 (dd, J = 7.5, 1.7 Hz, 1H), 7.00 (dd, J = 8.1, 1.0 Hz, 1H), 6.91 ± 6.86 (m, 
2H), 4.35 (d, J = 6.5 Hz, 2H), 3.60 (s, 2H); 13C NMR (101 MHz, CDCl3) GC 174.0, 156.0, 134.0, 
130.9, 130.2, 129.7, 129.3, 127.9, 124.2, 120.0, 118.0, 43.1, 40.9; HRMS (ESI) m/z: [M+H]+ Calcd 
for C15H16NO2 242.1176, Found 242.1177. 
N-(2-Hydroxyethyl)-N-methyl-2-phenylacetamide (11a).31 Yellow oil (249 mg, 91%): Xmax 
(neat) 3339, 3129, 2900, 1641, 1500 cm-1; 1H NMR (400 MHz, CDCl3) GH 7.36 ± 7.30 (m, 2H), 7.28 ± 
7.25 (m, 3H), 3.82 (s, 0.73H, minor rotamer), 3.76 ± 3.73 (m, 2.47H, major + minor rotamers), 3.65 (t, 
J = 5.4 Hz, 0.75H, minor rotamer,), 3.55 (t, 1.28H, J = 5.4 Hz, major rotamer,), 3.43 (t, J = 5.4 Hz, 
0.84H, minor rotamer,) 3.32 (br. s, 1H), 3.06 (s, 1.85H, major rotamer), 2.96 (s, 1.10H, minor 
rotamer); 13C NMR (101 MHz, CDCl3, major rotamer) GC 172.9, 134.7, 128.9, 128.8, 126.9, 60.8, 
51.3, 41.1, 37.2; 13C NMR (101 MHz, CDCl3, minor rotamer) GC 172.3, 135.5, 129.0, 128.6, 126.8, 
59.5, 52.4, 40.6, 33.9;  HRMS (ESI) m/z: [M+H]+ Calcd for C11H16NO2 194.1176, Found 194.1173. 
N,N-Bis(2-hydroxyethyl)-2-phenylacetamide (11b). White solid (279 mg, 88%): Xmax (neat) 
3329, 3204, 2903, 1601, 1479 cm-1; 1H NMR (500 MHz, DMSO): GH 7.31 ± 7.28 (m, 2H), 7.22 ± 7.20 
(m, 3H), 4.86 (t, J = 5.3 Hz, 1H), 4.65 (t, J = 5.3 Hz, 1H), 3.73 (s, 2H), 3.52 (q, J = 5.7 Hz, 2H), 3.48 
(q, J = 5.9 Hz, 2H), 3.43 (t, J = 5.8 Hz, 2H), 3.36 (t, J = 6.2 Hz, 2H); 13C NMR (126 MHz, DMSO) GC 
170.6, 136.3, 129.0, 128.2, 126.2, 59.2, 58.8, 50.8, 48.4, 1C missing (coincident); HRMS (ESI) m/z: 
[M+Na]+ Calcd for C12H17NO3Na 246.1101, Found 246.1099. 
3-Bromo-N-(2-hydroxyethyl)benzamide (12d). White solid (343 mg, 99%): Xmax (neat) 3360, 
3291, 3065, 2951, 1636, 1541 cm-1; 1H NMR (500 MHz, DMSO) GH 8.55 (t, J = 5.2 Hz, 1H), 8.04 (t, 
J = 1.8 Hz, 1H), 7.86 ± 7.84 (m, 1H), 7.72 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 
3.51 (t, J = 6.2 Hz, 2H), 3.32 (q, J = 6.1 Hz, 2H), 1H missing (exchangeable); 13C NMR (126 MHz, 
DMSO) GC 164.8, 136.7, 133.8, 130.5, 129.9, 126.3, 121.6, 59.6, 42.3; HRMS (ESI) m/z: [M+Na]+ 
Calcd for C9H10BrNO2Na 265.9784, Found 265.9785. 
2-Bromo-N-(2-hydroxyethyl)benzamide (12e). White solid (332 mg, 96%): Xmax (neat) 3412, 
3220, 3066, 2928, 1623, 1558 cm-1; 1H NMR (400 MHz, CDCl3) GH 7.57 (dd, J = 8.0, 1.1 Hz, 1H), 
7.50 (dd, J = 7.6, 1.8 Hz, 1H), 7.34 (td, J = 7.5, 1.2 Hz, 1H), 7.28 ± 7.24 (m, 1H), 6.58 (br. s, 1H), 
3.82 (t, J = 4.8 Hz, 2H), 3.60 (q, J = 5.2 Hz, 2H), 2.70 (br. s, 1H); 13C NMR (101 MHz, CDCl3) GC 
168.8, 137.7, 133.5, 131.6, 129.6, 127.8, 119.5, 62.0, 42.9; HRMS (ESI) m/z: [M+Na]+ Calcd for 
C9H10BrNO2Na 265.9784, Found 265.9784. 
1-Benzyl-N-(2-hydroxyethyl)piperidine-4-carboxamide (12g).Yellow oil (245 mg, 66%): Xmax 
(neat) 3437, 3233, 2922, 1651, 1599, 1537 cm-1; 1H NMR (400 MHz, DMSO) GH 7.71 (t, J = 5.5 Hz, 
1H), 7.33 ± 7.26 (m, 4H), 7.25 ± 7.21 (m, 1H), 4.62 (t, J = 5.5 Hz, 1H), 3.42 (s, 2H), 3.38 ± 3.33 (m, 
2H), 3.08 (q, J = 6.1 Hz, 2H), 2.79 (d, J = 11.5 Hz, 2H), 2.10 ± 2.03 (m, 1H), 1.87 (td, J = 11.4, 3.0 
Hz, 2H), 1.63 ± 1.49 (m, 4H); 13C NMR (101 MHz, CDCl3): GC 176.5, 138.3, 129.3, 128.4, 127.3, 
63.4, 62.4, 53.2, 43.5, 42.5, 29.1; HRMS (ESI) m/z: [M+H]+ Calcd for C15H23N2O2 263.1754, Found 
263.1752. 
2-(3-Cyanophenoxy)-N-(2-hydroxyethyl)-2-(naphthalen-1-yl)acetamide (12h). Colourless oil 
(298 mg, 61%): Xmax (neat) 3350, 3098, 2958, 2232, 1661, 1530, 1248 cm-1; 1H NMR (400 MHz, 
CDCl3) GH 8.30 (d, J = 8.4 Hz, 1H), 7.90 (dd, J = 12.5, 8.1 Hz, 2H), 7.66 ± 7.56 (m, 3H), 7.52 ± 7.43 
(m, 2H), 7.34 ± 7.23 (m, 2H), 7.22 ± 7.10 (m, 1H), 7.01 ± 6.91 (m, 1H), 6.28 (s, 1H), 3.70 (t, J = 5.1 
Hz, 2H), 3.58 (s, 1H), 3.50 (q, J = 5.2 Hz, 2H); 13C NMR (101 MHz, CDCl3) GC 157.0, 156.9, 134.3, 
131.4, 131.2, 130.9, 130.3, 129.3, 127.4, 126.5, 126.2, 125.5, 123.9, 123.6, 120.9, 120.0, 118.4, 113.7, 
78.7, 66.5, 38.3; HRMS (ESI) m/z: [M+H]+ Calcd for C21H19N2O3 347.1390, Found 347.1392. 
N-(2-Hydroxyethyl)pyrazine-2-carboxamide (12j). White solid (161 mg, 68%): Xmax (neat) 
3410, 3261, 2940, 1666, 1564 cm-1; 1H NMR (400 MHz, DMSO) GH 9.18 (d, J = 1.5 Hz, 1H), 8.87 (d, 
J = 2.5 Hz, 1H), 8.78 (t, J = 5.2 Hz, 1H), 8.73 ± 8.72 (m, 1H), 4.81 (t, J = 5.6 Hz, 1H), 3.53 (q, J = 6.0 
Hz, 2H), 3.39 (q, J = 6.1 Hz, 2H); 13C NMR (101 MHz, DMSO) GC 162.8, 147.5, 144.7, 143.5, 143.3, 
59.5, 41.6; HRMS (ESI) m/z: [M+H]+ Calcd for C7H10N3O2 168.0768, Found 168.0765. 
2-Chloro-N-(3-hydroxypropyl)-6-methylpyrimidine-4-carboxamide (12k). Yellow oil (261 
mg, 80%): Xmax (neat) 3365, 3101, 1671, cm-1; 1H NMR (500 MHz, CDCl3) GH 8.12 (br. s, 1H), 7.91 
(s, 1H), 3.70 (t, J = 5.4 Hz, 2H), 3.64 (q, J = 6.4 Hz, 2H), 2.87 (br. s, 1H), 2.64 (s, 3H), 1.87 ± 1.82 
(m, 2H); 13C NMR (126 MHz, CDCl3) GC 173.7, 162.8, 160.3, 158.8, 117.0, 59.6, 36.7, 32.3, 24.6; 
HRMS (ESI) m/z: [M+H]+ Calcd for C9H13N3O2Cl 230.0961, Found 230.0960. 
N-(3-Hydroxypropyl)-6-methylnicotinamide (12l). White solid (207 mg, 75%): Xmax (neat) 
3444, 3237, 2926, 2895, 1651, 1539 cm-1; 1H NMR (500 MHz, CDCl3) GH 8.85 (d, J = 2.1 Hz, 1H), 
8.03 (dd, J = 8.1, 2.3 Hz, 1H), 7.44 (br. s, 1H), 7.21 (d, J = 8.1 Hz, 1H), 3.76 (t, J = 5.5 Hz, 2H), 3.62 
(q, J = 5.9 Hz, 2H), 2.58 (s, 3H), 1.85 ± 1.80 (m, 2H), 1H missing (exchangeable); 13C NMR (126 
MHz, CDCl3) GC 166.5, 161.7, 147.4, 135.9, 127.6, 123.4, 60.6, 38.2, 31.8, 24.6; HRMS (ESI) m/z: 
[M+Na]+ Calcd for C10H14N2O2Na 217.0941, Found 217.0945. 
N-(2-Hydroxyethyl)-4H-1,2,4-triazole-3-carboxamide (12m). White solid (62 mg, 28%): Xmax 
(neat) 3406, 3273, 3102, 2982, 1644, 1563 cm-1; 1H NMR (400 MHz, DMSO) GH 8.43 (s, 1H), 4.78 
(br. s, 1H), 3.49 (t, J = 6.2 Hz, 2H), 3.34 ± 3.30 (m, 3H), 1H missing (exchangeable); 13C NMR (101 
MHz, DMSO) GC 158.2, 147.0, 59.5, 41.4, 1C missing (coincident); HRMS (ESI) m/z: [M+H]+ Calcd 
for C5H9N4O2 157.0720, Found 157.0718. 
N-(2-Hydroxyethyl)-1-methyl-1H-1,2,4-triazole-5-carboxamide (12n). White solid (227 mg, 
94%): Xmax (neat) 3237, 3101, 1671, 1580 cm-1; 1H NMR (400 MHz, CDCl3) GH 7.87 (br. s, 1H), 7.82 
(s, 1H), 4.25 (s, 3H), 3.83 (t, J = 5.2 Hz, 2H), 3.60 (q, J = 5.5 Hz, 2H), 3.01 (br. s, 1H); 13C NMR (101 
MHz, CDCl3) GC 157.9, 149.5, 146.3, 61.6, 42.2, 38.5; HRMS (ESI) m/z: [M+Na]+ Calcd for 
C6H10N4O2Na 193.0691, Found 193.0693. 
N-(2-Hydroxyethyl)-1H-pyrrole-2-carboxamide (12o). Yellow oil (201 mg, 92%): Xmax (neat) 
3277, 2940, 2878, 1607, 1560 cm-1; 1H NMR (400 MHz, DMSO) GH 11.41 (br. s, 1H), 7.96 (t, J = 5.6 
Hz, 1H), 6.83 (td, J = 2.7, 1.5 Hz, 1H), 6.76 ± 6.74 (m, 1H), 6.06 (dt, J = 3.6, 2.4 Hz, 1H), 4.72 (br. s, 
1H), 3.47 (t, J = 6.3 Hz, 2H), 3.27 (q, J = 6.1 Hz, 2H); 13C NMR (101 MHz, DMSO) GC 160.9, 126.4, 
121.2, 109.9, 108.5, 60.1, 41.4; HRMS (ESI) m/z: [M+Na]+ Calcd for C7H10N2O2Na 177.0632, Found 
177.0631. 
N-(2-Hydroxyethyl)pyrimidine-2-carboxamide (12p). White solid (195 mg, 82%); Also 
prepared as follows: To a solution of pyrimidine-2-carboxylic acid (176 mg, 1.42 mmol) and Et3N 
(395 ȝ/PPRO) in CH2Cl2 (1 mL) was added HATU (648 mg, 1.7 mmol) and ethanolamine (86 
ȝ/PPRO7KH UHDFWLRQPL[WXUHZDV VWLUUHd at room temperature for 16 h, then washed with 
water and 2M HCl, dried (MgSO4), filtered, and concentrated to a residue that was purified by flash 
column chromatography (4% methanol/ CH2Cl2) to afford the title compound as a white solid (180 
mg, 76%). Xmax (neat) 3403, 3310, 2919, 1651, 1538 cm-1; 1H NMR (400 MHz, CDCl3) GH 8.85 (d, J = 
4.8 Hz, 2H), 8.48 (br. s, 1 H), 7.42 (t, J = 4.9 Hz, 1H), 3.87 ± 3.85 (m, 2H), 3.68 (q, J = 5.8 Hz, 2H), 
3.36 (br. s, 1H); 13C NMR (101 MHz, CDCl3) GC 163.3, 157.7, 157.6, 122.8, 62.0, 42.8, 1C missing 
(coincident); HRMS (ESI) m/z: [M+H]+ Calcd for C7H10N3O2 168.0768, Found 168.0765. 
N-(2-Hydroxyethyl)-5-methoxy-3,4-dihydro-2H-pyrrole-2-carboxamide (12s). White solid 
(136 mg, 61%): Xmax (neat) 3410, 3277, 3090, 2931, 1663, 1647, 1559 cm-1; 1H NMR (500 MHz, 
DMSO) GH 8.20 (t, J = 4.8 Hz, 1H), 4.73 (br. s, 1H), 4.02 ± 4.00 (m, 1H), 3.42 (t, J = 6.0 Hz, 2H), 
3.15 (q, J = 5.8 Hz, 2H), 2.60 (s, 3H), 2.26 ± 2.15 (m, 3H), 1.81 ± 1.76 (m, 1H); 13C NMR (126 MHz, 
DMSO): GC 174.5, 171.1, 61.8, 59.7, 41.5, 29.3, 27.9, 22.5; HRMS (ESI) m/z: [M+H]+ Calcd for 
C8H15N2O3 187.1077, Found 187.1075. 
5-(4-Bromophenyl)-N-(2-hydroxyethyl)-3-methylisoxazole-4-carboxamide (12t). White solid 
(305 mg, 66%): Xmax (neat) 3271, 3112, 2955, 1643, 1545 cm-1; 1H NMR (400 MHz, CDCl3) GH 7.70 ± 
7.67 (m, 2H), 7.65 ± 7.63 (m, 2H), 6.13 (br. s, 1H), 3.78 (t, J = 5.0 Hz, 2H), 3.56 (q, J = 5.2 Hz, 2H), 
2.46 (s, 3H), 1.96 (br. s, 1H); 13C NMR (101 MHz, CDCl3) GC 167.1, 162.9, 160.0, 132.6, 129.6, 
126.0, 125.7, 112.3, 61.9, 42.4, 11.2; HRMS (ESI) m/z: [M+H]+ Calcd for C13H14BrN2O3 325.0182, 
Found 325.0184. 
(S)-(4-bromo-2-chlorophenyl)(2-(hydroxymethyl)pyrrolidin-1-yl)methanone (13a).
15
 2.5 g 
scale. To an oven-GULHG6FKOHQNWXEHFRQWDLQLQJ%(03ȝ/PPRODQGDFHWRQLWULOHP/ZDV
added methyl 4-bromo-2-chlorobenzoate (12.5 g, 10 mmol) and (S)-(+)-2-(hydroxymethyl)pyrrolidine 
ȝ/PPRO7KHUHDFWLRQPL[WXUHZDVVWLUUHGDWURRPWHPSHUDWXUHIRUKWKHQFRQFHQWUDWHG
to a residue that was purified by flash column chromatography (4% methanol/ CH2Cl2) to afford the 
title compound as a colourless oil (2.92 g, 92%): Xmax (neat) 3389, 2949, 2876, 1612, 1581, 1425 cm-1; 
1H NMR (500 MHz, CDCl3) GH 7.60 (d, J = 1.5 Hz, 1H), 7.48 (dd, J = 8.3, 1.8 Hz, 1H), 7.21 (d, J = 
8.0 Hz, 1H), 4.36 (qd, J = 7.3, 3.6 Hz, 1H), 3.82 (dd, J = 11.5, 3.0 Hz, 1H), 3.76 (dd, J = 11.8, 7.3 Hz, 
1H), 3.27 ± 3.26 (m, 2H), 2.20 ± 2.15 (m, 1H), 1.92 ± 1.87 (m, 1H), 1.86 ± 1.77 (m, 1H), 1.74 ± 1.67 
(m, 1H), 1H missing (exchangeable); 13C NMR (126 MHz, CDCl3) GC 168.3, 136.0, 132.7, 130.9, 
128.8, 123.7, 66.8, 61.8, 49.6, 28.8, 24.7, 1C missing (coincident); HRMS (ESI) m/z: [M+H]+ Calcd 
for C12H14BrClNO2 317.9891, Found 317.9896; [Į@D20 ±50 (c 2.0, CHCl3). 
(S,E)-1-(2-(Hydroxymethyl)pyrrolidin-1-yl)-3-phenylprop-2-en-1-one (13b).32 Yellow oil (302 
mg, 92%): Xmax (neat) 3350, 2949, 2876, 1645, 1582, 1422 cm-1; 1H NMR (400 MHz, CDCl3) GH 7.63 
± 7.56 (m, 1H), 7.45 ± 7.42 (m, 2H), 7.31 ± 7.20 (m, 3H), 6.90 (d, J = 15.2 Hz, 0.23H, minor 
rotamer), 6.66 (d,  J = 15.2 Hz, 0.73H,  major rotamer), 5.30 (br. s, 1H), 4.23 (app. quin, J = 5.7 Hz, 
0.75H major rotamer), 4.15 ± 4.10 (m, 0.27H, minor rotamer), 3.61 ± 3.47 (m, 4H, major + minor 
rotamers), 1.98 ± 1.86 (m, 2H, major + minor rotamers), 1.84 ± 1.76 (m, 1.2H, major rotamer), 1.69 ± 
1.62 (m, 0.78H, minor rotamer); 13C NMR (101 MHz, CDCl3, major rotamer) GC 166.6, 142.6, 134.8, 
129.7, 128.7, 127.8, 118.3, 65.9, 60.8, 47.8, 27.8, 24.1; 13C NMR (101 MHz, CDCl3, minor rotamer) 
GC 165.3, 141.4, 135.1, 129.2, 128.5, 127.7, 119.1, 64.1, 58.9, 46.1, 28.2, 21.7; HRMS (ESI) m/z: 
[M+H]+ Calcd for C14H18NO2 232.1332, Found 232.1331; [Į]D20 ±39 (c 2.1, MeOH). 
(S)-(2-(Hydroxymethyl)pyrrolidin-1-yl)(1H-indol-5-yl)methanone (13d). Colourless oil (197 
mg, 57%): Xmax (neat) 3318, 3211, 2963, 2891, 2846, 1629, 1554 cm-1; 1H NMR (400 MHz, DMSO) 
GH 11.25 (s, 1H), 7.72 (br. s, 1H), 7.41 ± 7.40 (m, 2H), 7.25 ± 7.24 (m, 1H), 6.49 (t, J = 2.0 Hz, 1H), 
4.81 (s, 1H), 4.18 ± 4.08 (m, 1H), 3.68 ± 3.59 (m, 1H), 3.52 ± 3.49 (m, 2H), 3.42 ± 3.38 (m, 1H), 1.98 
± 1.87 (m, 3H), 1.66 (br. s, 1H); 13C NMR (126 MHz, DMSO) GC 170.3, 136.3, 128.1, 126.7, 126.4, 
120.7, 119.8, 110.8, 101.8, 61.8, 58.7, 50.5, 27.2, 24.7; HRMS (ESI) m/z: [M+H]+ Calcd for 
C14H17N2O2 245.1285, Found 245.1284; [Į]D20 ±139 (c 1.0, MeOH). 
N-Benzyl-N-(2-hydroxyethyl)-2-phenylacetamide (13g). White solid (371 mg, 97%): Xmax 
(neat) 3399, 3333, 3063, 2934, 1624, 1489 cm-1; 1H NMR (400 MHz, CDCl3) GH 7.35 ± 7.19 (m, 8H), 
7.17 ± 7.15 (m, 1H), 7.09 (d, J = 6.8 Hz, 1H), 4.62 (s, 0.73H, minor rotamer), 4.58 (s, 1.27H, major 
rotamer), 3.86 (s, 0.77H, minor rotamer), 3.72 ± 3.67 (m, 2.41H, major rotamer), 3.59 (t, J = 5.4 Hz, 
0.76H, minor rotamer), 3.53 (t, J = 5.0 Hz, 1.30H, major rotamer), 3.34 (t, J = 5.6 Hz, 0.71H, minor 
rotamer), 2.43 (br. s, 1H); 13C NMR (101 MHz, CDCl3, major rotamer) GC 174.0, 136.4, 134.8, 129.2, 
129.0, 128.8, 128.1, 127.2, 126.6, 62.3, 53.1, 49.4, 41.4; 13C NMR (101 MHz, CDCl3, minor rotamer) 
GC 174.0, 137.9, 135.5, 129.1, 128.9, 128.7, 128.2, 127.6, 127.0, 60.3, 50.3, 48.8, 41.0; HRMS (ESI) 
m/z: [M+H]+ Calcd for C17H20NO2 270.1489, Found 270.1489. 
5-(4-Bromophenyl)-N-(2-hydroxyethyl)-N,3-dimethylisoxazole-4-carboxamide (13h). 
Colourless oil (433 mg, 90%): Xmax (neat) 3399, 2934, 1612, 1398 cm-1; 1H NMR (400 MHz, CDCl3, 
major rotamer): GH 7.64 ± 7.55 (m, 4H), 3.85 (t, J = 5.4 Hz, 1.30H, major rotamer), 3.70 (s, 1.13H, 
major rotamer), 3.49 (t, J = 4.8 Hz, 0.64H minor rotamer), 3.10 (s, 1.03H, minor rotamer), 2.85 (s, 
3H), 2.30 (s, 2H, major rotamer), 2.27 (s, 0.98H, minor rotamer), 1H missing (exchangeable); 13C 
NMR (101 MHz, CDCl3, major rotamer) GC 164.9, 164.5, 159.1, 132.6, 128.0, 125.7, 125.5, 111.4, 
60.2, 50.1, 37.2, 10.4; 13C NMR (101 MHz, CDCl3, minor rotamer) GC 164.4, 164.1, 159.5, 132.5, 
127.9, 125.8, 125.3, 111.8, 58.8, 52.8, 33.0, 10.3, 1C missing (overlapping peaks); HRMS (ESI) m/z: 
[M+H]+ Calcd for C14H16BrN2O3 339.0339, Found 339.0336. 
N,N-Bis(2-hydroxyethyl)-2-phenylacetamide (13i).33 White solid (279 mg, 81%): Xmax (neat) 
3329, 3204, 2903, 1601, 1479 cm-1; 1H NMR (500 MHz, DMSO) GH 7.74 (d, J = 8.0 Hz, 1H), 7.30 ± 
7.24 (m, 4H), 7.22 ± 7.19 (m, 1H), 4.60 (t, J = 5.3 Hz, 2H), 3.72 ± 3.66 (m, 1H), 3.43 (s, 2H), 3.40 (t, 
J = 5.3 Hz, 4H); 13C NMR (126 MHz, DMSO) GC 170.0, 136.6, 129.0, 128.1, 126.2, 60.1 52.9, 42.3; 
HRMS (ESI) m/z: [M+Na]+ Calcd for C11H15NO3Na 232.0944, Found 232.0941. 
N-(2-Hydroxy-2-methylpropyl)-4-(trifluoromethyl)benzamide (13l). White solid (189 mg, 
51%): Xmax (neat) 3447, 3312, 2980, 1639, 1547 cm-1; 1H NMR (500 MHz, DMSO) GH 8.47 (t, J = 6.0 
Hz, 1H), 8.05 (d, J = 8.1 Hz, 2H), 7.84 (d, J = 8.3 Hz, 2H), 4.54 (s, 1H), 3.27 (d, J = 6.2 Hz, 2H), 1.11 
(s, 6H); 13C NMR (126 MHz, DMSO) GC 165.6, 138.6, 131.0 (q, 2JCF = 32.2 Hz), 128.2, 125.2 (q, 3JCF 
= 3.2 Hz), 124.0 (q, 1JCF = 272.2 Hz), 69.8, 50.3, 27.4; HRMS (ESI) m/z: [M+Na]
+ Calcd for 
C12H14NO2F3Na 284.0869, Found 284.0867. 
(S)-4-Benzyloxazolidin-2-one (14a).25 White solid (171 mg, 68%): Xmax (neat) 3263, 2921, 
1707 cm-1; 1H NMR (400 MHz, CDCl3) GH 7.35 (tt, J = 8.1, 1.8 Hz, 2H), 7.30 (dt, J = 5.1, 2.1 Hz, 
1H), 7.20 ± 7.17 (m, 2H), 5.19 (br. s, 1H), 4.50 ± 4.46 (m, 1H), 4.17 (dd, J = 8.5, 5.6 Hz, 1H), 4.13 ± 
4.06 (m, 1H), 2.93 ± 2.84 (m, 2H); 13C NMR (126 MHz, CDCl3) GC 159.4, 136.2, 129.2, 129.1, 127.5, 
69.9, 54.0, 41.7; HRMS (ESI) m/z: [M+H]+ Calcd for C10H12NO2 178.0863, Found 178.0858; [Į]D20 ±
60 (c 1.0, CHCl3), lit
34 [Į]D20 ±62 (c 1.0, CHCl3). 
(S)-4-Phenyloxazolidin-2-one (14b).35 White solid (153 mg, 66%): Xmax (neat) 3237, 3142, 
1705 cm-1; 1H NMR (400 MHz, CDCl3  GH 7.44 ± 7.33 (m, 5H), 6.12 (br. s, 1H), 4.97 (t, J = 7.8 Hz, 
1H), 4.74 (t, J = 8.7 Hz, 1H), 4.19 (dd, J = 8.6, 6.9 Hz, 1H); 13C NMR (101 MHz, CDCl3) GC 160.0, 
139.7, 129.4, 129.0, 126.2, 72.7, 56.6; HRMS (ESI) m/z: [M+Na]+ Calcd for C9H9NO2Na 186.0521, 
Found 186.0523; [Į]D20 +53 (c 2.0, CHCl3), lit36 [Į@D20 +48 (c 2.0, CHCl3). 
(S)-4-Isopropyloxazolidin-2-one (14c).34 White solid (154 mg, 84%): Xmax (neat) 3253, 3153, 
2958, 1721, 1472 cm-1; 1H NMR (500 MHz, CDCl3): GH 6.23 (br. s, 1H), 4.45 (t, J = 8.6 Hz, 1H), 4.11 
(dd, J = 8.7, 6.3 Hz, 1H), 3.64 ± 3.59 (m, 1H), 1.74 (dq, J = 13.5, 6.8 Hz, 1H), 0.97 (d, J = 6.7 Hz, 
3H), 0.91 (d, J = 6.8 Hz, 3H); 13C NMR (126 MHz, CDCl3) GC 160.7, 68.8, 58.6, 32.9, 18.2, 17.8; 
HRMS (ESI) m/z: [M+H]+ Calcd for C6H12NO2 130.0863, Found 130.0862; [Į]D20 +6 (c 1.0, CHCl3), 
lit37 [Į]D20 +8 (c 1.0, CHCl3). 
Oxazolidin-2-one (14d).33 White solid (73 mg, 51%): Xmax (neat) 3248, 2989, 2919, 1712, 
1485 cm-1; 1H NMR (500 MHz, DMSO) GH 7.45 (br. s, 1H), 4.30 ± 4.27 (m, 2H), 3.46 ± 3.42 (m, 2H); 
13C NMR (126 MHz, CDCl3) GC 161.2, 65.2, 40.8; HRMS (EI) m/z: [M]+ Calcd for C3H5NO2 87.0315, 
Found 87.0316. 
(S)-Tetrahydropyrrolo[1,2-c]oxazol-3(1H)-one (14e).
38
 Yellow oil (125 mg, 69%):  
Xmax (neat): 2974, 2911, 1738, 1481 cm-1; 1H NMR (400 MHz, CDCl3įGGJ = 8.9, 7.9 Hz, 
1H), 4.10 (dd, J = 8.9, 3.6 Hz, 1H), 3.88 ± 3.81 (m, 1H), 3.60 ± 3.53 (m, 1H), 3.13 ± 3.08 (m, 1H), 
2.07 ± 1.97 (m, 2H), 1.93 ± 1.83 (m, 1H), 1.46 ± 1.36 (m, 1H); 13C NMR (101 MHz, CDCl3) G 161.8, 
67.8, 59.5, 45.8, 30.7, 25.7; HRMS (ESI) m/z: [M+H]+ Calcd for C6H10NO2 128.0706, Found 
128.0704; [Į]D20 ±68 (c 2.3, MeOH). 
4-(Hydroxymethyl)oxazolidin-2-one (14f).
39
 Yellow oil (144 mg, 87%):  
Xmax (neat): 3331, 3242, 2933, 2878, 1722, 1418 cm-1; 1H NMR (500 MHz, DMSOį7.57 (s, 1H), 
4.94 (t, J = 5.4 Hz, 1H), 4.30 (t, J = 8.6 Hz, 1H), 4.05 (dd, J = 8.5, 5.0 Hz, 1H), 3.78 ± 3.71 (m, 1H), 
3.37 ± 3.35 (m, 2H); 13C NMR (126 MHz, DMSO) G 159.1, 64.4, 62.7, 53.2; HRMS (ESI) m/z: 
[M+H]+ Calcd for C4H8NO3 118.0499, Found 118.0496. 
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